We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Signs Contract to Deliver Shipment of Four Million Allplex SARS-CoV-2/FluA/FluB/RSV Assay to Brazil

By LabMedica International staff writers
Posted on 24 Feb 2022

Seegene, Inc. (Seoul, Korea) has signed a supply deal with the Ministry of Health of Brazil to deliver four million COVID-19 tests.

Since January 2022, Brazil has battled a 'twindemic,' a rapid surge in both Flu A and COVID-19 infections due to the rapid spread of the Omicron variant. More seriously, new daily cases of COVID-19 have recently exceeded 280,000 cases, which is the highest figure since the first outbreak of the pandemic. While the country has been seeking to accelerate its quarantine efforts, there is a growing demand for COVID-19 tests as well. In response, Seegene will deliver a shipment of four million Allplex SARS-CoV-2/FluA/FluB/RSV Assay, capable of identifying respiratory viruses including COVID-19, Flu A/B as well as RSV in a single test. This assay is expected to be the optimized solution in Brazil where they are experiencing a rapid surge in both COVID-19 and Flu A cases.

Meanwhile, in January this year, Seegene introduced Allplex SARS-CoV-2 Fast PCR Assay, a new assay optimized for mass testing. This assay can deliver PCR results in just 60 minutes enabling large-scale laboratories to easily scale up the testing volume up to three times without additional instruments. The launch of the new assay is a response to the rapid spread of the latest Omicron variant, globally. The new assay is expected to be the optimized choice for large-scale laboratories and help them immediately expand the testing capacity.

"Seegene is uniquely positioned to respond to the growing global need for COVID-19 and flu testing and we are fully prepared to supply global inventory to help countries around the world as they fight for everyday life to return," said Ho Yi, Chief Sales and Marketing Officer of Seegene.

Related Links:
Seegene, Inc.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.